JP2020507584A - 癌選択的標識および標的化のためのトリガー活性化可能な糖コンジュゲート - Google Patents

癌選択的標識および標的化のためのトリガー活性化可能な糖コンジュゲート Download PDF

Info

Publication number
JP2020507584A
JP2020507584A JP2019543387A JP2019543387A JP2020507584A JP 2020507584 A JP2020507584 A JP 2020507584A JP 2019543387 A JP2019543387 A JP 2019543387A JP 2019543387 A JP2019543387 A JP 2019543387A JP 2020507584 A JP2020507584 A JP 2020507584A
Authority
JP
Japan
Prior art keywords
compound
alkyl
moiety
compound according
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2019543387A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507584A5 (enExample
Inventor
チェン，ジエンジュン
ツァイ，カイミン
ユィ，ジン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois System filed Critical University of Illinois System
Publication of JP2020507584A publication Critical patent/JP2020507584A/ja
Publication of JP2020507584A5 publication Critical patent/JP2020507584A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019543387A 2017-02-10 2018-02-12 癌選択的標識および標的化のためのトリガー活性化可能な糖コンジュゲート Abandoned JP2020507584A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762457597P 2017-02-10 2017-02-10
US62/457,597 2017-02-10
PCT/US2018/017802 WO2018148650A1 (en) 2017-02-10 2018-02-12 Trigger-activatable sugar conjugates for cancer-selective labeling and targeting

Publications (2)

Publication Number Publication Date
JP2020507584A true JP2020507584A (ja) 2020-03-12
JP2020507584A5 JP2020507584A5 (enExample) 2021-03-25

Family

ID=63107851

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019543387A Abandoned JP2020507584A (ja) 2017-02-10 2018-02-12 癌選択的標識および標的化のためのトリガー活性化可能な糖コンジュゲート

Country Status (6)

Country Link
US (1) US11299509B2 (enExample)
EP (1) EP3595729A4 (enExample)
JP (1) JP2020507584A (enExample)
KR (1) KR20190126314A (enExample)
CN (1) CN110520161A (enExample)
WO (1) WO2018148650A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
CN107073090A (zh) 2014-04-30 2017-08-18 哈佛学院董事会 结合的疫苗装置和杀死癌细胞的方法
US11752238B2 (en) 2016-02-06 2023-09-12 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
JP2019522486A (ja) 2016-07-13 2019-08-15 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗原提示細胞模倣足場およびそれを作製および使用するための方法
KR102638898B1 (ko) 2016-08-02 2024-02-22 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 면역 반응을 조정하기 위한 생체재료
US11299509B2 (en) 2017-02-10 2022-04-12 The Board Of Trustees Of The University Of Illinois Trigger-activatable sugar conjugates for cancer-selective labeling and targeting
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
WO2021024256A1 (en) * 2019-08-05 2021-02-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Anticancer agents
WO2021155297A1 (en) * 2020-01-29 2021-08-05 President And Fellows Of Harvard College Methods for labeling and targeting cells
JP2024504475A (ja) * 2021-01-28 2024-01-31 南京▲樺▼冠生物技▲術▼有限公司 複合体およびその使用
US20250255977A1 (en) * 2021-11-08 2025-08-14 Shanghai Best-Link Bioscience, Llc Epsilon-poly-l-lysine-based drug conjugate, intermediate thereof, and application thereof
WO2024120466A1 (en) * 2022-12-08 2024-06-13 Surio Therapeutics Co., Ltd Monosaccarides, pharmaceutical compositions, and diagnostic and therapeutic applications
CN116239640B (zh) * 2023-01-19 2024-03-08 中国药科大学 吉西他滨前药及其医药用途
CN116655715B (zh) * 2023-07-27 2023-10-20 北京炫景瑞医药科技有限公司 一种GalNAc衍生物、缀合物、组合物以及它们的用途
WO2025036407A1 (en) * 2023-08-15 2025-02-20 Surio Therapeutics Co. Ltd. Aldh-activable funtionalized monosaccarides, pharmaceutical compositions, and diagnostic and therapeutic applications
CN118603851A (zh) * 2024-05-22 2024-09-06 杭州瑞奥生物医药有限公司 一种检测细胞表面叠氮的两步法荧光标记流式方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1102785T3 (da) * 1999-06-07 2013-05-13 Arrowhead Res Corp Sammensætninger til lægemiddeltilførsel ved anvendelse af pH-følsomme molekyler
LT1912671T (lt) * 2005-07-18 2017-12-11 Seattle Genetics, Inc. Vaisto konjugatai, turintys gliukoronido linkerį
EP2877480B1 (en) * 2012-06-28 2017-09-06 Universiteit Gent Galactopyranosyl derivatives useful as medicaments
CN105142672B (zh) 2012-10-23 2019-04-05 西纳福克斯股份有限公司 经修饰的抗体、抗体-缀合物及其制备方法
WO2014085275A1 (en) * 2012-11-30 2014-06-05 University Of Massachusetts Medical School Multi-functional surface coating of implants
AU2013364065B2 (en) 2012-12-21 2018-10-04 Altrubio Inc. Hydrophilic self-immolative linkers and conjugates thereof
US9695189B2 (en) 2013-03-01 2017-07-04 Mark Quang Nguyen Chemical crosslinkers and compositions thereof
ES2865473T3 (es) 2013-07-10 2021-10-15 Sutro Biopharma Inc Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
WO2015021305A1 (en) 2013-08-09 2015-02-12 The Research Foundation For The State Univeristy Of New York Cancer cell specific imaging probes and methods of use
US10550190B2 (en) * 2014-04-04 2020-02-04 Merck Sharp & Dohme Corp. Phosphate based linkers for intracellular delivery of drug conjugates
CN107406463A (zh) * 2014-12-04 2017-11-28 细胞基因公司 生物分子共轭物
PL3250237T3 (pl) * 2015-01-30 2021-12-13 Sutro Biopharma, Inc. Pochodne hemiasterliny do koniugacji i terapii
JP6892694B2 (ja) * 2015-10-07 2021-06-23 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ 癌選択性標識化及び標的指向化のためのトリガー活性型代謝糖前駆体
US11299509B2 (en) 2017-02-10 2022-04-12 The Board Of Trustees Of The University Of Illinois Trigger-activatable sugar conjugates for cancer-selective labeling and targeting

Also Published As

Publication number Publication date
KR20190126314A (ko) 2019-11-11
US20190367550A1 (en) 2019-12-05
CN110520161A (zh) 2019-11-29
EP3595729A4 (en) 2022-01-12
EP3595729A1 (en) 2020-01-22
US11299509B2 (en) 2022-04-12
WO2018148650A1 (en) 2018-08-16

Similar Documents

Publication Publication Date Title
US11299509B2 (en) Trigger-activatable sugar conjugates for cancer-selective labeling and targeting
JP6892694B2 (ja) 癌選択性標識化及び標的指向化のためのトリガー活性型代謝糖前駆体
US10905762B2 (en) Targeted nanoparticle conjugates
JP6932389B2 (ja) 標的化コンジュゲートならびにその粒子及び製剤
JP6223824B2 (ja) 新規な自己反応性アーム及び同物を含むプロドラッグ
EP2347770B2 (de) Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
JP6721512B2 (ja) がん及び炎症性疾患の治療のための結合体及びプロドラッグ
JP6543342B2 (ja) 血清半減期を延長するための、調節可能リンカーを介した薬学的活性剤とトランスサイレチンリガンドのコンジュゲーション
CA3150890A1 (en) Fibroblast activation protein (fap)-targeted imaging and therapy of cancers and other fibrotic and inflammatory diseases
US10793595B2 (en) Toll-like receptor 2 ligands and methods of making and using thereof
US12281161B2 (en) Polypeptides and uses thereof
Lu et al. Design, synthesis, and biological evaluation of cathepsin B cleavage albumin-binding SN38 prodrug in breast cancer
JP7620569B2 (ja) がん治療のための新規治療用ベクター及びプロドラッグ
CN101410139A (zh) 施陶丁格连接在生物活性化合物的体内组装中的用途
CN106344930A (zh) 分子定点靶向和激活的短肽阿霉素的制备和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210212

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20210412